Trial Profile
Clinical study to evaluate the efficacy, pharmacokinetics and safety of immunoglobulin intravenous (human) 10% (NewGam) in patients with primary immunodeficiency diseases.
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 31 May 2022
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Bacterial infections; Immunodeficiency disorders
- Focus Therapeutic Use
- Sponsors Octapharma
- 17 Nov 2009 New trial record